My NCBISign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 207

    1.

    Plasma PCSK9 levels are significantly modified by statins and fibrates in humans.

    Mayne J, Dewpura T, Raymond A, Cousins M, Chaplin A, Lahey KA, Lahaye SA, Mbikay M, Ooi TC, Chrétien M.

    Lipids Health Dis. 2008 Jun 11;7:22.PMID: 18547436 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels.

    Davignon J, Dubuc G.

    Trans Am Clin Climatol Assoc. 2009;120:163-73.PMID: 19768174 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Plasma PCSK9 levels correlate with cholesterol in men but not in women.

    Mayne J, Raymond A, Chaplin A, Cousins M, Kaefer N, Gyamera-Acheampong C, Seidah NG, Mbikay M, Chrétien M, Ooi TC.

    Biochem Biophys Res Commun. 2007 Sep 21;361(2):451-6. Epub 2007 Jul 18.PMID: 17645871 [PubMed - indexed for MEDLINE]Related articles

    4.

    Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

    Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ.

    J Lipid Res. 2008 Feb;49(2):394-8. Epub 2007 Nov 21.PMID: 18033751 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.

    Kourimate S, Le May C, Langhi C, Jarnoux AL, Ouguerram K, Zaïr Y, Nguyen P, Krempf M, Cariou B, Costet P.

    J Biol Chem. 2008 Apr 11;283(15):9666-73. Epub 2008 Feb 3.PMID: 18245819 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.

    Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, Hammer RE, Moon YA, Horton JD.

    Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5374-9. Epub 2005 Apr 1.PMID: 15805190 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    A new method for measurement of total plasma PCSK9: clinical applications.

    Dubuc G, Tremblay M, Paré G, Jacques H, Hamelin J, Benjannet S, Boulet L, Genest J, Bernier L, Seidah NG, Davignon J.

    J Lipid Res. 2010 Jan;51(1):140-9. Epub .PMID: 19571328 [PubMed - indexed for MEDLINE]Related articles

    8.

    Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9.

    Humphries SE, Neely RD, Whittall RA, Troutt JS, Konrad RJ, Scartezini M, Li KW, Cooper JA, Acharya J, Neil A.

    Clin Chem. 2009 Dec;55(12):2153-61. Epub 2009 Oct 1.PMID: 19797716 [PubMed - indexed for MEDLINE]Related articles

    9.

    Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.

    Zaid A, Roubtsova A, Essalmani R, Marcinkiewicz J, Chamberland A, Hamelin J, Tremblay M, Jacques H, Jin W, Davignon J, Seidah NG, Prat A.

    Hepatology. 2008 Aug;48(2):646-54.PMID: 18666258 [PubMed - indexed for MEDLINE]Related articles

    10.

    Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.

    Sharma R, Mahajan M, Singh B, Bal BS, Kant R.

    J Indian Med Assoc. 2006 Sep;104(9):492-4, 496, 498.PMID: 17388006 [PubMed - indexed for MEDLINE]Related articles

    11.

    Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.

    Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, Prat A.

    Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1454-9. Epub 2004 Jun 3.PMID: 15178557 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease.

    Cao G, Qian YW, Kowala MC, Konrad RJ.

    Endocr Metab Immune Disord Drug Targets. 2008 Dec;8(4):238-43. Review.PMID: 19075777 [PubMed - indexed for MEDLINE]Related articles

    13.

    Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol.

    Alborn WE, Cao G, Careskey HE, Qian YW, Subramaniam DR, Davies J, Conner EM, Konrad RJ.

    Clin Chem. 2007 Oct;53(10):1814-9. Epub 2007 Aug 16.PMID: 17702855 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells.

    Leblond F, Seidah NG, Précourt LP, Delvin E, Dominguez M, Levy E.

    Am J Physiol Gastrointest Liver Physiol. 2009 Apr;296(4):G805-15. Epub 2009 Jan 29.PMID: 19179626 [PubMed - indexed for MEDLINE]Related articles

    15.

    Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment.

    Lambert G, Ancellin N, Charlton F, Comas D, Pilot J, Keech A, Patel S, Sullivan DR, Cohn JS, Rye KA, Barter PJ.

    Clin Chem. 2008 Jun;54(6):1038-45. Epub 2008 Apr 24.PMID: 18436719 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

    Maxwell KN, Breslow JL.

    Proc Natl Acad Sci U S A. 2004 May 4;101(18):7100-5. Epub 2004 Apr 26.PMID: 15118091 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.

    Lopez D.

    Drug News Perspect. 2008 Jul-Aug;21(6):323-30. Review.PMID: 18836590 [PubMed - indexed for MEDLINE]Related articles

    18.

    Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice.

    Luo Y, Warren L, Xia D, Jensen H, Sand T, Petras S, Qin W, Miller KS, Hawkins J.

    J Lipid Res. 2009 Aug;50(8):1581-8. Epub 2008 Dec 6.PMID: 19060325 [PubMed - indexed for MEDLINE]Related articles

    19.

    Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis.

    Qian YW, Schmidt RJ, Zhang Y, Chu S, Lin A, Wang H, Wang X, Beyer TP, Bensch WR, Li W, Ehsani ME, Lu D, Konrad RJ, Eacho PI, Moller DE, Karathanasis SK, Cao G.

    J Lipid Res. 2007 Jul;48(7):1488-98. Epub 2007 Apr 20.PMID: 17449864 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men.

    Gouni-Berthold I, Berthold HK, Gylling H, Hallikainen M, Giannakidou E, Stier S, Ko Y, Patel D, Soutar AK, Seedorf U, Mantzoros CS, Plat J, Krone W.

    Atherosclerosis. 2008 May;198(1):198-207. Epub 2007 Nov 5.PMID: 17980884 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity

    You are here: NCBI > Literature > PubMed
    Write to the Help Desk